<DOC>
	<DOCNO>NCT02607449</DOCNO>
	<brief_summary>Drug-resistant tuberculosis become major problem whole humanity , development new Anti-TB drug great importance . Since Kazakhstan country high burden tuberculosis , The Government The Republic Kazakhstan found initiative development new Anti-TB drug treat drug-resistant form infectious disease . JSC `` Scientific Center Anti-infectious Drugs '' develop original drug FS-1 treatment multidrug resistant tuberculosis ( MDR-TB ) .</brief_summary>
	<brief_title>FS-1 Drug Treatment Multiple Drug-resistant Tuberculosis</brief_title>
	<detailed_description>Phase 3 clinical study FS-1 drug randomize , interventional , multicenter , placebo-controlled ( add-on ) , double-blind two arm trial . The study consist two follow phase : treatment phase - 12 month follow-up phase 12 month . It plan recruit 480 patient verified MDR-TB diagnosis . All data compile Electronic Data Capture System statistical analysis accord approve Statistical Analytical Plan .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>Subjects suffer multidrugresistant form pulmonary tuberculosis define : confirmed growth M. tuberculosis sputum sample obtain screen obtained culture method describe detail appendix protocol . resistance isoniazid rifampicin demonstrate drug susceptibility test ( BK+ ) liquid MGIT BACTEC medium preservation sensitivity fluoroquinolones aminoglycoside/capreomycin Subjects fo ethnicity , intellectually capable understand condition requirement study protocol Willing freely und voluntarily provide informed consent agreement sec . 8 ICH E6 ( ICH E6 , 2002 ) Willing capable comply requirement protocol Pregnancy breastfeeding ; Patients decompensated concomitant disease ( cardiovascular , renal , hepatic failure ) may affect conduct study ; Patients severe mental disorder ; Patients allergy iodinecontaining drug , hypersensitivity iodine ; intolerance secondline drug ; Epidermomycosis Socially maladjusted patient suffer alcoholism drug addiction ; Hypothyroidism ; Hashimoto 's thyroiditis ; The use TB treatment two month start study ; Nonadherence DOTS+ therapy ; Serious side and/or adverse effect ; Decision subject terminate his/her participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>